Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Orchiectomy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02077634
What this trial is testing

Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Who this might be right for
Prostate Cancer
Universität des Saarlandes 68
Early research (Phase 1)Study completedNCT05585034
What this trial is testing

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamous+6 more
Xencor, Inc. 60
Early research (Phase 1)Active Not RecruitingNCT06229366
What this trial is testing

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more
Eli Lilly and Company 142
Testing effectiveness (Phase 2)Study completedNCT01503229
What this trial is testing

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more
University of Washington 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT04592237
What this trial is testing

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Who this might be right for
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
M.D. Anderson Cancer Center 120
Testing effectiveness (Phase 2)Study completedNCT03643107
What this trial is testing

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer Patients
Allarity Therapeutics 15
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Not applicableWithdrawnNCT01692483
What this trial is testing

Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Neoplasms
Janssen Pharmaceutica
Testing effectiveness (Phase 2)Study completedNCT04060394
What this trial is testing

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Laekna Limited 49
Testing effectiveness (Phase 2)Ended earlyNCT03741712
What this trial is testing

SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 9
Not applicableStudy completedNCT06013475
What this trial is testing

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

Who this might be right for
Non-metastatic Castration-resistant Prostate Cancer
Bayer 1,375
Testing effectiveness (Phase 2)Active Not RecruitingNCT04655365
What this trial is testing

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

Who this might be right for
Prostate Cancer
CHU de Quebec-Universite Laval 50
Early research (Phase 1)Study completedNCT03481816
What this trial is testing

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Who this might be right for
Prostatic NeoplasmsProstatic Cancer
National Cancer Institute (NCI) 18
Not applicableStudy completedNCT03176381
What this trial is testing

Tissue Predictors of Abiraterone Benefit

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Tianjin Medical University Second Hospital 110
Testing effectiveness (Phase 2)UnknownNCT02691975
What this trial is testing

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Who this might be right for
Hormone Refractory Prostate CancerMetastatic Prostate Carcinoma
Jiangsu HengRui Medicine Co., Ltd. 197
Early research (Phase 1)Ended earlyNCT05037500
What this trial is testing

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8+1 more
Roswell Park Cancer Institute 8
Early research (Phase 1)Study completedNCT02106507
What this trial is testing

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 9
Large-scale testing (Phase 3)Active Not RecruitingNCT05348577
What this trial is testing

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
AstraZeneca 1,035
Testing effectiveness (Phase 2)Study completedNCT02020135
What this trial is testing

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Who this might be right for
Prostate Cancer
Progenics Pharmaceuticals, Inc. 9
Testing effectiveness (Phase 2)Study completedNCT02286921
What this trial is testing

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

Who this might be right for
Castration Resistant Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 222
Next Page